person · Reporting owner
Pacelli Steven Robert
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DEXCOM INCDXCM · Entity 3114 | EVP Managing Director Dexcom V | November 24, 2023 | November 27, 2023 |
| ProSomnus, Inc.OSA · Entity 94197 | Director | December 06, 2022 | February 16, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DEXCOM INC
Report date November 24, 2023 · Filed November 27, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 124,775 |
Reported balance
After 2023-11-24 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-11-24 · Sale · Disposed 411 · Balance 124,775 F1: On September 15, 2022, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan that was intended to comply with prior version of Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended. F2: Included in this number are 39,132 unvested restricted stock units, 18,776 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 15, 2022, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan that was intended to comply with prior version of Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended.
F2: Included in this number are 39,132 unvested restricted stock units, 18,776 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024.
ProSomnus, Inc.
Report date December 06, 2022 · Filed February 16, 2024 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,200 |
Reported balance
Holding disclosure · report date 2022-12-06 · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · Balance 18,200 F1: Holdings have been adjusted to rectify unintentional underreporting in the Reporting Person's Form 3. |
Filing footnotes · ownership attribution and instrument terms
F1: Holdings have been adjusted to rectify unintentional underreporting in the Reporting Person's Form 3.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 23, 2021 Filed Jul 27, 2021 22:03 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 279 | $450.82 | $125,777.41 |
DisclosureSEC source: 0001093557-21-000182 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,963 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $450.70 to $450.96. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| June 23, 2021 Filed Jun 24, 2021 21:59 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 459 | $427.67 | $196,300.35 |
DisclosureSEC source: 0001093557-21-000173 · edgardoc.xml · nonDerivative · entry 3 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,242 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $427.36 to $427.91. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| June 23, 2021 Filed Jun 24, 2021 21:59 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 540 | $426.60 | $230,364.32 |
DisclosureSEC source: 0001093557-21-000173 · edgardoc.xml · nonDerivative · entry 2 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,701 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $426.165 to $427.13. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| June 23, 2021 Filed Jun 24, 2021 21:59 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 80 | $424.84 | $33,986.80 |
DisclosureSEC source: 0001093557-21-000173 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,241 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $424.50 to $425.17. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| May 24, 2021 Filed May 26, 2021 20:57 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 60 | $351.05 | $21,063.20 |
DisclosureSEC source: 0001093557-21-000152 · edgardoc.xml · nonDerivative · entry 7 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,321 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F8 · price: This transaction was executed in multiple trades at prices ranging from $351.00 to $351.16. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| May 24, 2021 Filed May 26, 2021 20:57 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 455 | $350.43 | $159,446.70 |
DisclosureSEC source: 0001093557-21-000152 · edgardoc.xml · nonDerivative · entry 6 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,381 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $349.92 to $350.90. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| May 24, 2021 Filed May 26, 2021 20:57 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 160 | $349.39 | $55,902.80 |
DisclosureSEC source: 0001093557-21-000152 · edgardoc.xml · nonDerivative · entry 5 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,836 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $348.85 to $349.63. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| May 24, 2021 Filed May 26, 2021 20:57 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 80 | $347.68 | $27,814.20 |
DisclosureSEC source: 0001093557-21-000152 · edgardoc.xml · nonDerivative · entry 4 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,996 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $347.51 to $347.76. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| May 24, 2021 Filed May 26, 2021 20:57 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 184 | $346.68 | $63,788.57 |
DisclosureSEC source: 0001093557-21-000152 · edgardoc.xml · nonDerivative · entry 3 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,076 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $346.45 to $346.74. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| May 24, 2021 Filed May 26, 2021 20:57 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 80 | $345.26 | $27,621.00 |
DisclosureSEC source: 0001093557-21-000152 · edgardoc.xml · nonDerivative · entry 2 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,260 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $345.18 to $345.34. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| May 24, 2021 Filed May 26, 2021 20:57 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 60 | $343.73 | $20,623.80 |
DisclosureSEC source: 0001093557-21-000152 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,340 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| April 23, 2021 Filed Apr 27, 2021 00:09 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 347 | $411.32 | $142,727.10 |
DisclosureSEC source: 0001093557-21-000117 · edgardoc.xml · nonDerivative · entry 3 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,400 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $411.21 to $411.48. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| April 23, 2021 Filed Apr 27, 2021 00:09 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 436 | $410.69 | $179,058.97 |
DisclosureSEC source: 0001093557-21-000117 · edgardoc.xml · nonDerivative · entry 2 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,747 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $409.965 to $410.820. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| April 23, 2021 Filed Apr 27, 2021 00:09 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 296 | $408.58 | $120,941.07 |
DisclosureSEC source: 0001093557-21-000117 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,183 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $408.55 to $408.64. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 00:18 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 166 | $362.30 | $60,141.42 |
DisclosureSEC source: 0001093557-21-000093 · edgardoc.xml · nonDerivative · entry 5 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,479 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $362.13 to $362.45. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 00:18 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 229 | $360.90 | $82,645.66 |
DisclosureSEC source: 0001093557-21-000093 · edgardoc.xml · nonDerivative · entry 4 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,645 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $360.805 to $361.590. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 00:18 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 589 | $360.36 | $212,252.51 |
DisclosureSEC source: 0001093557-21-000093 · edgardoc.xml · nonDerivative · entry 3 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,874 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $359.69 to $360.67. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 00:18 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 77 | $358.13 | $27,576.01 |
DisclosureSEC source: 0001093557-21-000093 · edgardoc.xml · nonDerivative · entry 2 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,463 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 00:18 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 18 | $352.88 | $6,351.84 |
DisclosureSEC source: 0001093557-21-000093 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,540 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 22:40 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 5,566 | $362.92 | $2,019,996.02 |
DisclosureSEC source: 0001093557-21-000076 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,558 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| March 08, 2021 Filed Mar 11, 2021 00:28 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 5,301 | $0.00 | $5.30 |
DisclosureSEC source: 0001093557-21-000053 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,124 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock. F2 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| February 23, 2021 Filed Feb 25, 2021 00:57 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,079 | $406.98 | $439,131.42 |
DisclosureSEC source: 0001093557-21-000030 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,823 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 22,722 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 7,494 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 6,417 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 23:33 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,800 | $420.01 | $756,025.02 |
DisclosureSEC source: 0001093557-21-000028 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,902 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $420.00 to $420.22. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 22,722 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 7,494 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 6,417 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 01:21 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 18 | $372.77 | $6,709.88 |
DisclosureSEC source: 0001093557-21-000012 · edgardoc.xml · nonDerivative · entry 4 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,702 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $372.635 to $372.880. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 22,722 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 7,494 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 6,417 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 01:21 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 373 | $369.96 | $137,994.48 |
DisclosureSEC source: 0001093557-21-000012 · edgardoc.xml · nonDerivative · entry 3 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,720 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $369.44 to $370.34. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 22,722 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 7,494 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 6,417 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 01:21 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 310 | $368.88 | $114,353.14 |
DisclosureSEC source: 0001093557-21-000012 · edgardoc.xml · nonDerivative · entry 2 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,093 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $368.43 to $369.16. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 22,722 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 7,494 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 6,417 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 01:21 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 378 | $367.47 | $138,902.41 |
DisclosureSEC source: 0001093557-21-000012 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,403 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $366.84 to $367.66. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 22,722 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 7,494 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 6,417 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| December 23, 2020 Filed Dec 28, 2020 22:43 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 20 | $364.68 | $7,293.60 |
DisclosureSEC source: 0001093557-20-000331 · edgardoc.xml · nonDerivative · entry 7 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,781 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · balance_after: Included in this number are 22,722 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 7,494 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 6,417 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| December 23, 2020 Filed Dec 28, 2020 22:43 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 60 | $364.00 | $21,840.20 |
DisclosureSEC source: 0001093557-20-000331 · edgardoc.xml · nonDerivative · entry 6 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,801 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F8 · price: This transaction was executed in multiple trades at prices ranging from $363.54 to $364.24. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 22,722 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 7,494 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 6,417 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| December 23, 2020 Filed Dec 28, 2020 22:43 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 87 | $361.99 | $31,493.03 |
DisclosureSEC source: 0001093557-20-000331 · edgardoc.xml · nonDerivative · entry 5 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,861 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $361.90 to $362.22. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 22,722 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 7,494 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 6,417 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| December 23, 2020 Filed Dec 28, 2020 22:43 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 153 | $361.11 | $55,249.75 |
DisclosureSEC source: 0001093557-20-000331 · edgardoc.xml · nonDerivative · entry 4 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,948 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $360.85 to $361.35. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 22,722 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 7,494 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 6,417 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| December 23, 2020 Filed Dec 28, 2020 22:43 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 210 | $359.98 | $75,595.21 |
DisclosureSEC source: 0001093557-20-000331 · edgardoc.xml · nonDerivative · entry 3 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,101 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $359.73 to $360.25. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 22,722 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 7,494 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 6,417 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| December 23, 2020 Filed Dec 28, 2020 22:43 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 292 | $358.94 | $104,811.12 |
DisclosureSEC source: 0001093557-20-000331 · edgardoc.xml · nonDerivative · entry 2 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,311 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $358.59 to $359.25. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 22,722 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 7,494 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 6,417 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| December 23, 2020 Filed Dec 28, 2020 22:43 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 257 | $357.95 | $91,993.43 |
DisclosureSEC source: 0001093557-20-000331 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,603 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $357.43 to $358.36. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 22,722 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 7,494 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 6,417 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| November 23, 2020 Filed Nov 25, 2020 21:50 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,079 | $318.99 | $344,190.21 |
DisclosureSEC source: 0001093557-20-000318 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,860 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 22,722 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 7,494 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 6,417 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| October 23, 2020 Filed Oct 27, 2020 22:20 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 83 | $408.00 | $33,864.00 |
DisclosureSEC source: 0001093557-20-000298 · edgardoc.xml · nonDerivative · entry 7 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,939 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · balance_after: Included in this number are 22,722 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 7,494 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 6,417 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| October 23, 2020 Filed Oct 27, 2020 22:20 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 195 | $407.02 | $79,369.47 |
DisclosureSEC source: 0001093557-20-000298 · edgardoc.xml · nonDerivative · entry 6 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,022 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $406.75 to $407.33. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 22,722 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 7,494 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 6,417 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| October 23, 2020 Filed Oct 27, 2020 22:20 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 173 | $405.99 | $70,236.81 |
DisclosureSEC source: 0001093557-20-000298 · edgardoc.xml · nonDerivative · entry 5 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,217 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $405.58 to $406.30. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 22,722 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 7,494 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 6,417 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| October 23, 2020 Filed Oct 27, 2020 22:20 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 170 | $404.91 | $68,833.88 |
DisclosureSEC source: 0001093557-20-000298 · edgardoc.xml · nonDerivative · entry 4 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,390 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $404.37 to $404.93. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 22,722 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 7,494 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 6,417 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| October 23, 2020 Filed Oct 27, 2020 22:20 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 70 | $402.61 | $28,182.70 |
DisclosureSEC source: 0001093557-20-000298 · edgardoc.xml · nonDerivative · entry 3 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,560 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · balance_after: Included in this number are 22,722 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 7,494 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 6,417 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| October 23, 2020 Filed Oct 27, 2020 22:20 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 149 | $399.62 | $59,542.71 |
DisclosureSEC source: 0001093557-20-000298 · edgardoc.xml · nonDerivative · entry 2 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,630 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $399.36 to $399.63. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 22,722 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 7,494 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 6,417 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| October 23, 2020 Filed Oct 27, 2020 22:20 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 239 | $397.49 | $95,000.13 |
DisclosureSEC source: 0001093557-20-000298 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,779 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $397.025 to $398.00. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 22,722 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 7,494 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 6,417 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| October 01, 2020 Filed Oct 2, 2020 22:08 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 200 | $420.00 | $84,000.00 |
DisclosureSEC source: 0001093557-20-000274 · edgardoc.xml · nonDerivative · entry 3 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,018 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · balance_after: Included in this number are 22,722 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 7,494 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 6,417 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 22:08 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 100 | $411.10 | $41,110.00 |
DisclosureSEC source: 0001093557-20-000274 · edgardoc.xml · nonDerivative · entry 2 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,218 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · balance_after: Included in this number are 22,722 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 7,494 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 6,417 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 22:08 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,900 | $410.28 | $779,527.44 |
DisclosureSEC source: 0001093557-20-000274 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,318 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $410.00 to $410.945. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 22,722 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 7,494 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 6,417 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| September 25, 2020 Filed Sep 28, 2020 21:35 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,000 | $400.07 | $800,137.00 |
DisclosureSEC source: 0001093557-20-000272 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,218 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $400.00 to $400.155. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 22,722 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 7,494 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 6,417 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| September 23, 2020 Filed Sep 24, 2020 20:30 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,079 | $395.11 | $426,323.69 |
DisclosureSEC source: 0001093557-20-000268 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,218 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 22,722 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 7,494 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 6,417 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| September 09, 2020 Filed Sep 11, 2020 22:58 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,283 | $398.30 | $511,021.47 |
DisclosureSEC source: 0001093557-20-000254 · edgardoc.xml · nonDerivative · entry 2 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,297 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 22,722 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 7,494 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 6,417 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| September 09, 2020 Filed Sep 11, 2020 22:58 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,297 | $398.30 | $1,313,201.69 |
DisclosureSEC source: 0001093557-20-000254 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,580 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 22,722 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 7,494 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 6,417 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| August 24, 2020 Filed Aug 26, 2020 23:04 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,531 | $427.24 | $654,107.20 |
DisclosureSEC source: 0001093557-20-000234 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,877 F1 · shares: On June 11, 2019, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $426.49 to $427.41. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 31,636 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 9,991 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.